# A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Study · id `cardio:ct-nct06935370` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06935370](<https://clinicaltrials.gov/study/NCT06935370>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06935370

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4200 participants.

## Technical summary

Registry record NCT06935370. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-20 (actual); primary completion 2029-02-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4200 participants (planned count; ClinicalTrials.gov record NCT06935370, source copy `cardio:ctgov-nct06935370-2026-11-12`, retrieved 2026-11-18)
- Started: 2025-05-20 (actual) (ClinicalTrials.gov record NCT06935370, source copy `cardio:ctgov-nct06935370-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2029-02-04 (anticipated) (ClinicalTrials.gov record NCT06935370, source copy `cardio:ctgov-nct06935370-2026-11-12`, retrieved 2026-11-18)
- Completion: 2029-02-22 (anticipated) (ClinicalTrials.gov record NCT06935370, source copy `cardio:ctgov-nct06935370-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Argentina; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; Romania; Saudi Arabia; Serbia; Slovakia; South Korea; Spain; Taiwan; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT06935370, source copy `cardio:ctgov-nct06935370-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06935370-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
- Condition: Heart Failure
- Intervention (Drug): vicadrostat
- Intervention (Drug): empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

## Provenance

Content hash: fe83661dbd2fa8ffc97497c2270f67d173d316340ed6abd376f869fc990a6518
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
